Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped down before the market opened on Tuesday . The stock had previously closed at $24.28, but opened at $17.08. Dyne Therapeutics shares last traded at $18.69, with a volume of 2,729,682 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DYN. Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, August 17th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating on the stock. Finally, TD Cowen started coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Dyne Therapeutics Trading Down 20.9%

The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The stock’s 50-day simple moving average is $24.86 and its 200-day simple moving average is $20.45. The firm has a market capitalization of $3.59 billion, a PE ratio of -5.72 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. This trade represents a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,139,196 shares of company stock worth $99,449,852 in the last quarter. 9.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics in the first quarter worth $26,000. Strs Ohio bought a new position in Dyne Therapeutics in the fourth quarter worth $51,000. Allworth Financial LP purchased a new position in Dyne Therapeutics during the second quarter valued at $62,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the fourth quarter valued at $84,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.